Adding sonrotoclax to zanubrutinib led to deep and durable response in relapsed or refractory mantle cell lymphoma, according ...

Eli Lilly said on Tuesday its drug for a type of blood cancer was more effective in a head-to-head study against AbbVie's Imbruvica when tested in both untreated and previously treated patients. The ...

Beerse: Janssen-Cilag International NV, a Johnson & Johnson company, has announced that the European Commission (EC) has approved an indication extension of IMBRUVICA (ibrutinib) in ...

DelveInsight’s, “ Small Lymphocytic Lymphoma Pipeline Insight, 2025 ” report provides comprehensive insights about 80+ ...

Researchers recommend that details on prescription medications received in the year before diagnosis and treatment initiation be included in clinical trials as essential baseline information.

The ROR inhibitors market is witnessing steady growth driven by the increasing understanding of receptor tyrosine kinase-like orphan receptor ...

Monday said that the European Patent Office (EPO) has issued a notice of allowance for a composition of matter patent covering its drug candidate LP-284.

Lantern Pharma Inc. (NASDAQ: LTRN), a clinical-stage oncology company leveraging its proprietary RADR ® artificial intelligence (AI) platform to accelerate drug discovery, today announced that the ...

The National Institute for Health and Care Excellence (NICE) has recommended BeOne Medicines’ targeted cancer drug Brukinsa ...

Mantle cell lymphoma treatment offers options if patients relapse after CAR T-cell therapy, from bispecific antibodies, antibody drug conjugates, and other emerging therapies.

Researchers sought to determine whether dual-targeted CAR-T therapy would be effective for patients with relapsed or refractory MCL.

Follicular lymphoma is a blood cancer that originates in B cells, a type of immune cell that helps the body fight off harmful pathogens. It is the second most common type of non-Hodgkin lymphoma ...